Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
CRISPR Therapeutics AG (CRSP) closed at $53.84 in the latest trading session, marking a -4.54% move from the prior day.
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $55.16, representing a +2.58% change from its previous close.
Crispr Therapeutics: Prospects For 2026 - Why I Believe Casgevy Is Key
Crispr Therapeutics AG commands a $5bn valuation, anchored by Casgevy's commercial approval and robust clinical data in SCD and TDT. Casgevy's slow commercial ramp is expected to accelerate in 2026, with revenue and patient growth as key valuation drivers. CRSP's pipeline—spanning in-vivo, CAR-T, and diabetes assets—offers major upside, but Casgevy remains the only revenue source.
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.19, moving 1.45% from the previous trading session.
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $56.46, marking a -2.5% move from the previous day.
CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies
CRISPR Therapeutics shares jump after early zugo-cel study data show sustained B-cell depletion and early efficacy across autoimmune and cancer studies.
Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $54.74, indicating a -2.2% shift from the previous trading day.
Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy
Crispr Therapeutics AG remains a Strong Buy, driven by forthcoming revenue following Casgevy's FDA/EMA approvals and a robust, expanding pipeline targeting high-value indications. CRSP's commercial launch of Casgevy is progressing, with their share of a $100M+ 2025 total revenue expectation, and significant growth expected into 2026. The pipeline's cardiovascular assets (CTX310/320) show promising early efficacy, with huge addressable markets and the potential to disrupt standard-of-care regimens.
